{
  "source": "PA-Notification-Promacta.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1083-16\nProgram Prior Authorization/Notification\nMedication *Promacta® and Alvaiz™ (eltrombopag)\n*Promacta tablet formulation is excluded from coverage for the\nmajority of our benefits.\nP&T Approval Date 1/2012, 2/2013, 2/2014, 2/2015, 2/2016, 12/2016, 11/2017, 11/2018,\n11/2019, 11/2020, 11/2021, 1/2022, 1/2023, 1/2024, 6/2024, 8/2024\nEffective Date 1/1/2025\n1. Background:\nPromacta and Alvaiz (eltrombopag) are a thrombopoietin receptor agonists indicated for the\ntreatment of thrombocytopenia in adult and pediatric patients (1 year and older for Promacta and\n6 years and older for Alvaiz) with persistent or chronic immune thrombocytopenia (ITP) who\nhave experienced an insufficient response to corticosteroids, immunoglobulins, or splenectomy,\nfor the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation\nand maintenance of interferon-based therapy, and for the treatment of patients with severe\naplastic anemia who have had an insufficient response to immunosuppressive therapy. Promacta\nis also approved in combination with standard immunosuppressive therapy for the first line\ntreatment of adult and pediatric patients 2 years and older with severe aplastic anemia.\nPromacta and Alvaiz should be used only in patients with ITP whose degree of\nthrombocytopenia and clinical condition increase the risk for bleeding.\nPromacta and Alvaiz should be used only in patients with chronic hepatitis C whose degree of\nthrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to\nmaintain interferon-based therapy. Safety and efficacy have not been established in combination\nwith direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C\ninfection.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Chronic immune thrombocytopenia (ITP)\n1. Initial Authorization\na. *Promacta or Alvai",
    "onic hepatitis C\ninfection.\nMembers will be required to meet the coverage criteria below.\n2. Coverage Criteriaa:\nA. Chronic immune thrombocytopenia (ITP)\n1. Initial Authorization\na. *Promacta or Alvaiz will be approved based on both of the following criteria:\n(1) Diagnosis of chronic immune thrombocytopenia (ITP)\n-AND-\n(2) Patient has had an insufficient response to a previous treatment (e.g.,\ncorticosteroids, immunoglobulins, thrombopoietin receptor agonists,\n© 2024 UnitedHealthcare Services, Inc.\n1\nsplenectomy)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. *Promacta or Alvaiz will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Promacta or Alvaiz therapy\nAuthorization will be issued for 12 months.\nB. Chronic hepatitis C-associated thrombocytopenia\n1. Initial Authorization\na. *Promacta or Alvaiz will be approved based on both of the following criteria:\n(1) Diagnosis of chronic hepatitis C-associated thrombocytopenia\n-AND-\n(2) One of the following:\n(a) Planning to initiate and maintain interferon-based treatment\n-OR-\n(b) Currently receiving interferon-based treatment\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. *Promacta or Alvaiz will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Promacta or Alvaiz therapy\n-AND-\n(2) Patient is currently on antiviral interferon therapy for treatment of chronic\nhepatitis C\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\nC. Aplastic Anemia\n1. Initial Authorization\na. *Promacta or Alvaiz will be approved based on both of the following criteria:\n(1) Diagnosis of severe aplastic anemia\n-AND-\n(2) One of the following\n(a) Used in combination with standard immunosuppressive therapy (e.g.,\nAtgam [antithymocyte globulin equine], Thymoglobulin [antithymocyte\nglobulin rabbit], cyclosporine)\n-OR-\n(b) History of failure, contraindication, or intolerance to at least",
    "suppressive therapy (e.g.,\nAtgam [antithymocyte globulin equine], Thymoglobulin [antithymocyte\nglobulin rabbit], cyclosporine)\n-OR-\n(b) History of failure, contraindication, or intolerance to at least one course of\nimmunosuppressive therapy (e.g., Atgam [antithymocyte globulin equine],\nThymoglobulin [antithymocyte globulin rabbit], cyclosporine)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. *Promacta or Alvaiz will be approved based on the following criterion:\n(1) Documentation of positive clinical response to Promacta or Alvaiz therapy\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Promacta tablet formulation is excluded from coverage for the majority of our benefits.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n3. References:\n1. Promacta [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation;\nMarch 2023.\n2. Alvaiz [Package Insert]. Parsippany, NJ: Teva Pharmaceuticals; November 2023\n© 2024 UnitedHealthcare Services, Inc.\n3\nProgram Prior Authorization/Notification – Promacta (eltrombopag)\nChange Control\n2/2014 Annual review. Increased authorization to 60 months for ITP.\n9/2014 Administrative change – Tried/Failed exemption for State of New\nJersey removed.\n2/2015 Annual review. Added criteria for new aplastic anemia indication.\nUpdated background and references.\n2/2016 Annual review. Revised reauthorization criteria for thrombocytopenia\ndue to chronic hepatitis C. Extended initial authorization to 6 months\nfor chronic hepatitis C and aplastic anemia. Updated b",
    "/2016 Annual review. Revised reauthorization criteria for thrombocytopenia\ndue to chronic hepatitis C. Extended initial authorization to 6 months\nfor chronic hepatitis C and aplastic anemia. Updated background and\nreferences.\n12/2016 Annual review. Reduced ITP authorization to 6 months and added\nreauthorization criteria. Updated background and references.\n11/2017 Annual review. Updated references.\n11/2018 Annual review. Revised coverage rationale to rename idiopathic\nthrombocytopenic purpura to immune thrombocytopenia. Updated\nbackground and references.\n11/2019 Annual review. Revised coverage rationale for aplastic anemia.\nUpdated background and references.\n11/2020 Annual review. No changes to coverage rationale. Updated reference.\n11/2021 Annual review. No changes to coverage criteria. Updated reference.\n1/2022 Revised try/fail criteria to insufficient response. Updated reference.\n1/2023 Annual review with no changes to coverage criteria. Updated\nbackground per label and added state mandate.\n1/2024 Annual review. Reformatted criteria without change to clinical intent.\nUpdated background per label and updated reference.\n6/2024 Added Alvaiz to the program.\n8/2024 Added statement that the Promacta tablet formulation is excluded from\ncoverage for the majority of our benefits.\n© 2024 UnitedHealthcare Services, Inc.\n4"
  ]
}